Shares of Nabriva Therapeutics PLC – (NASDAQ:NBRV) have been assigned an average recommendation of “Buy” from the eleven brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $9.00.
Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Nabriva Therapeutics in a research note on Thursday. Northland Securities set a $13.00 price objective on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 8th. Gabelli upgraded shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 target price on the stock in a research report on Thursday, May 2nd. ValuEngine lowered shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 target price (down from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st.
Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in shares of Nabriva Therapeutics by 514.2% in the 4th quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock worth $2,690,000 after buying an additional 1,542,700 shares in the last quarter. Aisling Capital Management LP purchased a new stake in shares of Nabriva Therapeutics in the 4th quarter worth about $2,642,000. BlackRock Inc. boosted its position in shares of Nabriva Therapeutics by 99.5% in the 3rd quarter. BlackRock Inc. now owns 936,624 shares of the biotechnology company’s stock worth $2,529,000 after buying an additional 467,119 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Nabriva Therapeutics by 26.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 759,245 shares of the biotechnology company’s stock worth $1,853,000 after buying an additional 158,852 shares in the last quarter. Finally, Fosun International Ltd purchased a new stake in shares of Nabriva Therapeutics in the 1st quarter worth about $1,593,000. Institutional investors and hedge funds own 4.61% of the company’s stock.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Friday, May 10th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.56 million. Nabriva Therapeutics had a negative net margin of 1,188.69% and a negative return on equity of 101.03%. As a group, equities research analysts expect that Nabriva Therapeutics will post -1.18 EPS for the current fiscal year.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: Strangles
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.